---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-027083"
form_type: "8-K"
ticker: null
cik: "0001460602"
company_name: "Orgenesis Inc."
filed_at: "2024-07-12T23:59:59+00:00"
generated_at: "2026-05-31T21:05:52.934211+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Orgenesis acquires Theracell assets including TIL platform and 100% of Theracell IKE for $13M less $10.3M debt

## Summary
- Orgenesis to acquire 50% of Theracell IKE (to own 100%) plus five product platforms from Theracell for $13M valuation minus $10,324,241.79 debt.
- Net consideration ~$2.7M; paid $400k in 60 days, $250k in 1 year, remainder in four annual installments starting Dec 30, 2025.
- Products acquired include TIL manufacturing, 3rd-gen GMP lentivirus process, oncolytic virus cell carrier, MSC therapy for kidney, and transdermal delivery platform.
- Theracell owes Orgenesis $10.3M, effectively used as credit toward purchase price; Theracell indemnifies Orgenesis for pre-closing liabilities.
- Transaction closed July 12, 2024; Orgenesis gains intellectual property and ownership of Theracell IKE.

## SEC filing metadata
- accession: 0001493152-24-027083
- form_type: 8-K
- cik: 0001460602
- company_name: Orgenesis Inc.
- filed_at: 2024-07-12T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 2.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1460602/000149315224027083/0001493152-24-027083-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1460602/000149315224027083/from8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-027083
- JSON: https://secwatch.observer/filing/0001493152-24-027083.json
- Plain text: https://secwatch.observer/filing/0001493152-24-027083.txt

## Key facts
- M&A Transactions
  Orgenesis Inc. completed an acquisition involving Theracell Advanced Biotechnology S.A, Theracell Advanced Biotechnology LTD and IDNA Genomics Public Limited for $13,000,000 (closed 2024-07-12).
  - Action: acquisition
  - Counterparty: Theracell Advanced Biotechnology S.A, Theracell Advanced Biotechnology LTD and IDNA Genomics Public Limited
  - Consideration: $13,000,000
  - Closing: 2024-07-12
  source text: in the Purchase Agreement. Pursuant to the Purchase Agreement, in consideration for the purchase of the Assets, the Company will pay Theracell an aggregate purchase price of $13,000,000 (the “Consideration”), which is equal to the value of the Assets established by a third-party valuation firm selected by the Company, less a debt adjustment in the amount of
  evidence_url: https://www.sec.gov/Archives/edgar/data/1460602/000149315224027083/0001493152-24-027083-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.